Skip to content

M B Leal

3 papers in the library · 41 citations · publishing 2000-2006

Papers

Sort Most recent Most cited

Nature-inspired indolyl-2-azabicyclo[2.2.2]oct-7-ene derivatives as promising agents for the attenuation of withdrawal symptoms: synthesis of 20-desethyl-20-hydroxymethyl-11-demethoxyibogaine.

Natural Product Research July 10, 2006 Daniele Passarella, A Barilli, Simon M. N. Efange et al. 4 citations

Microwave assisted Diels-Alder cycloaddition of 5-Br-N-benzylpyridinone (2) with methyl acrylate is described to gain an easy access to 7-bromo-2-benzyl-3-oxo-2-aza-5 or 6-carbomethoxy bicyclo[2.2.2]oct-7-enes (3)-(6). The preparation of the ibogaine analogue 20-desethyl-(20-endo)-hydroxymethyl-11-demethoxyibogaine (17) is described by stereoselective hydrogenation of the C(7)-C(8) double bond....

Ibogaine alters synaptosomal and glial glutamate release and uptake.

Neuroreport February 12, 2001 M B Leal, T Emanuelli, L D Porciúncula et al. 14 citations

Ibogaine has aroused expectations as a potentially innovative medication for drug addiction. It has been proposed that antagonism of the NMDA receptor by ibogaine may be one of the mechanisms underlying its antiaddictive properties; glutamate has also been implicated in ibogaine-induced neurotoxicity. We here report the effects of ibogaine on [3H]glutamate release and uptake in cortical and...

Long-lasting ibogaine protection against NMDA-induced convulsions in mice.

Neurochemical Research August 1, 2000 M B Leal, D O De Souza, E Elisabetsky 23 citations

Ibogaine, a putative antiaddictive drug, is remarkable in its apparent ability to downgrade withdrawal symptoms and drug craving for extended periods of time after a single dose. Ibogaine acts as a non-competitive NMDA receptor antagonist, while NMDA has been implicated in long lasting changes in neuronal function and in the physiological basis of drug addiction. The purpose of this study was...